Organization (Other)
Friends Research Institute
ClinicalTrials.gov lists Friends Research Institute as lead sponsor of 44 trials. It has 12 active development programs and 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Friends Research Institute: 44 lead-sponsored trials and 1 legal-entity registration.
Disease areas (22)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Substance-Related Disorders | 47 |
| Opioid-Related Disorders | 28 |
| HIV Infections | 10 |
| Acquired Immunodeficiency Syndrome | 6 |
| Heroin Dependence | 4 |
Showing 5 of 22 disease areas.
Trials by start year as sponsor or collaborator (23)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 7 |
| 2024 | 4 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 6 |
| 2019 | 6 |
| 2018 | 3 |
| 2017 | 3 |
Showing 10 of 23 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 34 months across 35 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (12)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Extended Release Buprenorphine | Opioid-Related Disorders | Phase 3 | 2 |
| Extended Release Buprenorphine | Substance-Related Disorders | Phase 3 | 2 |
| XR-NTX | Opioid-Related Disorders | Phase 3 | 2 |
| XR-NTX | Substance-Related Disorders | Phase 3 | 2 |
| Methadone Treatment-As-Usual | Opioid-Related Disorders | Phase 3 | 2 |
Showing 5 of 12 active programs.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Buprenorphine + naloxone (Suboxone) | 2 |
| Buprenorphine | 2 |
| Extended Release Naltrexone | 1 |
| Methadone | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 29% hit target (n=14) | 35% on time (n=17) |
Journals published in (56)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of substance abuse treatment | 9 |
| AIDS and behavior | 7 |
| JMIR research protocols | 6 |
| Addiction (Abingdon, England) | 5 |
| Addiction science & clinical practice | 5 |
Showing 5 of 56 journals.
Financing and grant events (54)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-26 | NIH grant | 783,321 | Reporter |
| 2025-09-05 | NIH grant | 1,393,922 | Reporter |
| 2025-09-03 | NIH grant | 677,620 | Reporter |
| 2025-08-01 | NIH grant | 901,066 | Reporter |
| 2025-07-31 | NIH grant | 1,130,715 | Reporter |
Showing 5 of 54 events.
Organization relationships (11)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of California System | Co sponsors trial with | 7 |
| Government of the United States of America | Co sponsors trial with | 2 |
| Leiden University Medical Center | Co sponsors trial with | 1 |
| The Fenway Institute | Co sponsors trial with | 1 |
| Labcorp Holdings Inc. | Co sponsors trial with | 1 |
Showing 5 of 11 relationships.
Latest dated events (119)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-26 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-10-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-26 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 119 events.
CLIA clinical laboratory certificates (3)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| FRIENDS RESEARCH INSTITUTE INC | Certificate of waiver | Terminated |
| FRIENDS RESEARCH INSTITUTE | Certificate of waiver | Terminated |
| FRIENDS RESEARCH INSTITUTE, INC | Certificate of waiver | Terminated |
Biomarker capability evidence (17)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| COMMD3 | Trial collaborator | Named in trial inclusion criteria |
| MAPT | Trial sponsor | Named in trial inclusion criteria |
| OTP | Trial sponsor | Named in trial inclusion criteria |
| OTP | Trial sponsor | Named in trial inclusion criteria |
| TNFRSF17 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 17 evidence rows.
Biomarkers this organization publishes on (5)
Shown in this order: most publications first.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.